Catalyst Calendar
Scope

Tue, Jun 30, 2026

1 updates
VTGN
8:00 AM

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder Favorable safety and tolerability

Trial Results • Phase 3Topline results Tue, Jun 30, 2026vistagen.com

Mon, Jun 15, 2026

1 updates
VTGN
4:30 PM

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026 Achieved minimum ICH E1

Trial Results • Phase 3PALISADE-4 topline results Tue, Jun 30, 2026vistagen.com

Tue, Jun 9, 2026

1 updates

Wed, May 27, 2026

1 updates
VTGN
8:30 AM

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2026-- Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the

vistagen.com

Tue, May 19, 2026

1 updates
VTGN
8:30 AM

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

Dr. Angelov brings extensive industry experience across multiple therapeutic areas SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and

vistagen.com

Thu, May 14, 2026

1 updates

Tue, May 12, 2026

1 updates
VTGN
7:30 AM

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Fasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and

Interim Data • Phase 3Interim data Tue, May 12, 2026vistagen.com

Fri, May 8, 2026

1 updates
VTGN
7:30 AM

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 8, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to

Enrollment • Phase 3vistagen.com

Wed, Apr 22, 2026

1 updates
VTGN
8:30 AM

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 22, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today

vistagen.com